65,437 trials
Chronic Pain · Pain · Widespread Chronic Pain
Primary: Brief Pain Inventory-Intensity (BPI-Intensity) — 6.19; 5.42; 5.68; 5.95 units on a scale — p=.165
Childhood Lymphocyte-Depleted Classical Hodgkin Lymphoma · Childhood Mixed Cellularity Classical Hodgkin Lymphoma · Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma
Primary: Event-free Survival — 0.89; 0.87; 0.84; 0.87 Probability of survival
Pulmonary Disease, Chronic Obstructive
Primary: Mean Annual Rate of Moderate or Severe COPD Exacerbations — 1.90; 1.74 Exacerbations per participant per year — p==0.025
Locally Advanced Solid Tumor · Metastatic Solid Tumor · Breast Cancer
Primary: Number of Subjects With Dose Limiting Toxicities (DLT) — 0; 0; 0; 0 subjects
Psoriasis
Primary: Percentage of Participants With Greater Decrease In Overall Target Plaque Severity Score (OTPSS): Ointment (2% Twice Daily), Vehicle — 54.1; 2.7 percenatge of…
Migraine Headache
Primary: Migraine Relief at 2 Hours Post Stimulation
Herpes Zoster
Primary: Number of Vaccine Responders for Anti-gE Antibodies as Determined by ELISA — 74; 26; 26; 22 Participants
Solid Tumors
Primary: Number of Subjects With Dose Limiting Toxicities (DLTs) Determined in Part-A — 0; 0; 0; 0 subjects
Multiple Sclerosis, Relapsing-Remitting
Primary: Percentage of Subjects Rating Each Device as "Easy/Very Easy to Use" Based on User Trial Questionnaire (UTQ) at Week 4 — 34.8; 50.0; 39.1; 30.0 percentage of subjects
Hypogonadism · Primary Hypogonadism · Secondary Hypogonadism
Primary: Percentage of Participants Meeting Serum Total Testosterone Average Concentration Criteria for Responder During the 3rd Injection Interval in Part C — 94.0 percentage of…
Total Shoulder Arthroplasty
Primary: Comparing Glenoid Component Positioning to Pre Operative Planning — 4.3; 6.9 Degrees — p=0.11
Melanoma (Skin)
Primary: Progression-free Survival — 5.6; 5.1 months
Dermatitis, Atopic
Primary: Atopic Dermatitis Severity Index (ADSI) Score at Baseline (Day 1) — 8.0; 8.3; 8.0; 8.4 units on a scale
Pancreatic Cancer
Primary: Progression Free Survival — 2.07 months
Xerosis Cutis
Primary: Transepidermal Water Loss (TEWL) in g/m2/h at the Left Mid Volar Forearm — 10.0; 11.9 g/m2/h — p=0.002